Trial Profile
High dose AMBISOME on a fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: a Phase 3 randomised controlled non-Inferiority trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Amphotericin B liposomal (Primary) ; Amphotericin B; Fluconazole; Flucytosine
- Indications Cryptococcal meningitis
- Focus Therapeutic Use
- Acronyms AMBITION; Ambition-cm; Ambition-P3
- 08 Mar 2022 The aim of this study is to find out whether a single high dose of L-AmB is as effective as the standard treatment in terms of preventing deaths from cryptococcal meningitis hence I have indexed trial focus as TU.
- 21 Jul 2021 Primary endpoint (All-cause mortality within the first 10 weeks after randomisation (non-inferiority)) has been met as per results presented at the 11th International AIDS Society Conference on HIV Science
- 21 Jul 2021 Results presented at the 11th International AIDS Society Conference on HIV Science